ReviewACS applied bio materials2023
Recent Advances in Nanotherapeutics for Neurological Disorders.
Review in ACS applied bio materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Magnetic Field-Guided Magnetic Nanoparticles as Neurotherapeutics for Neurological Disorders and Glioblastoma.Life (Basel, Switzerland) · 2026Review
- The landscape of nanomedical clinical trials.Nano today · 2026Article
- Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS.Communications biology · 2025Review
- Carbon-based nanotechnology for Parkinson's disease: diagnostic and therapeutic innovations.Nanomedicine (London, England) · 2025Review
- Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- A Review of the Neuroprotective Properties of Exosomes Derived from Stem Cells and Exosome-Coated Nanoparticles for Treating Neurodegenerative Diseases and Stroke.International journal of molecular sciences · 2025Review
- Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies.Pharmaceutics · 2025Review
- Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease.The Lancet. Neurology · 2025Review
- Nanotechnology to Overcome Blood-Brain Barrier Permeability and Damage in Neurodegenerative Diseases.Pharmaceutics · 2025Review
- Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.Biomimetics (Basel, Switzerland) · 2025Review
- Unraveling Neurological Drug Delivery: Polymeric Nanocarriers for Enhanced Blood-Brain Barrier Penetration.Current drug targets · 2025Review
- Advancing CNS Therapeutics: Enhancing Neurological Disorders with Nanoparticle-Based Gene and Enzyme Replacement Therapies.International journal of nanomedicine · 2025Review
- ISR Modulators in Neurological Diseases.Current neuropharmacology · 2025Review
- Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments - a state-of-the-art update.Frontiers in pharmacology · 2025Review
- Nanomaterials engineered for photothermal therapy in neural tumors and neurodegenerative diseases: biomaterial design, clinical mechanisms and applications.Frontiers in bioengineering and biotechnology · 2025Review
- Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system.Journal of nanobiotechnology · 2024Review
- Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection.International journal of molecular sciences · 2024Review
- Strategies and delivery systems for cell-based therapy in autoimmunity.Frontiers in drug delivery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.